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Dysregulated methylation at imprinted genes in
prostate tumor tissue detected by methylation
microarray
Daniel I Jacobs1, Yingying Mao1,2, Alan Fu1, William Kevin Kelly3 and Yong Zhu1*
Abstract
Background: Imprinting is an important epigenetic regulator of gene expression that is often disrupted in cancer.
While loss of imprinting (LOI) has been reported for two genes in prostate cancer (IGF2 and TFPI2), disease-related
changes in methylation across all imprinted gene regions has not been investigated.
Methods: Using an Illumina Infinium Methylation Assay, we analyzed methylation of 396 CpG sites in the promoter
regions of 56 genes in a pooled sample of 12 pairs of prostate tumor and adjacent normal tissue. Selected LOI
identified from the array was validated using the Sequenom EpiTYPER assay for individual samples and further
confirmed by expression data from publicly available datasets.
Results: Methylation significantly increased in 52 sites and significantly decreased in 17 sites across 28 unique
genes (P < 0.05), and the strongest evidence for loss of imprinting was demonstrated in tumor suppressor genes
DLK1, PLAGL1, SLC22A18, TP73, and WT1. Differential expression of these five genes in prostate tumor versus normal
tissue using array data from a publicly available database were consistent with the observed LOI patterns, and WT1
hypermethylation was confirmed using quantitative DNA methylation analysis.
Conclusions: Together, these findings suggest a more widespread dysregulation of genetic imprinting in prostate
cancer than previously reported and warrant further investigation.
Keywords: Imprinting, Prostate cancer, Differential methylation, DLK1, PLAGL1, SLC22A18, TP73, WT1
Background
Genomic imprinting is the epigenetic phenomenon by
which alleles of select genes are differentially expressed
according to the parent of origin [1]. In humans, ap-
proximately 65 genes have been validated as imprinted
[2]. It has been suggested that imprinting is regulated
primarily by DNA methylation of imprinting control re-
gions (ICRs), which is established in the germ line and
maintained throughout subsequent development [3].
Loss of monoallelic expression at imprinted genes,
known as loss of imprinting (LOI), has been associated
with many cancer types including leukemia, colorectal,
liver, and lung cancer [4] and may play a role as an early
driver in tumorigenesis [5]. Abnormal methylation of
imprinted genes can be detrimental given frequent roles
in promoting and restricting cellular growth. For ex-
ample, loss of methylation of the maternal allele of
insulin-like growth factor-II (IGF2) has been associated
with increased expression of the growth-promoting gene
in Wilms’ tumor [6].
While studies have suggested a role for IGF2 and tis-
sue factor pathway inhibitor-2 (TFPI2) LOI in prostate
cancer [7-9], the literature is restricted largely to these
two genes. Here, we present a comprehensive investiga-
tion of methylation patterns at imprinted genes in pros-
tate cancer. Our results indicate an overall dysregulation
of imprinted gene methylation levels in prostate tumor
tissue as compared to adjacent normal tissue, with pro-
nounced gain of methylation at five tumor suppressor
genes.
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Methods
Study subjects
Procedures for participant recruitment have been de-
scribed previously [10]. Briefly, study subjects were identi-
fied via the Yale Cancer Center Rapid Case Ascertainment
system and all patients consented to the donation of tissue
to the Yale-New Haven Hospital (YNHH) tissue bank.
Samples were obtained according to protocols approved
by the Research Ethics Board from YNHH, New Haven
County, Connecticut and the Connecticut Department of
Public Health Human Investigations Committee. Tissue
sections from seventeen pairs of formalin-fixed paraffin-
embedded (FFPE) prostate cancers and corresponding ad-
jacent normal tissue specimens, obtained from patients
who had undergone surgery between 2005 and 2009 at
YNHH, were mounted on slides and examined by an ex-
pert pathologist. Gleason grades varied between speci-
mens, with a composite score ranging from 6 to 9. No
subjects who had received either chemo- or radio-therapy
were included in the study.
Isolation of genomic DNA
Sections of tumor and adjacent normal tissue were patho-
logically reviewed, manually microdissected, and collected
into 1.5 ml microtubes. The DNeasy Blood & Tissue Kit
(Qiagen, Valencia, CA) was used to isolate genomic DNA
according to the manufacturer’s protocols.
Methylation assay
Equal amounts of DNA from tumor and matching adjacent
normal tissue from twelve subjects (a sufficient amount of
DNA was unavailable for five of the seventeen subjects)
were combined by tissue type for CpG methylation micro-
array analysis. Methylation of imprinted genes was assessed
using the Illumina Infinium HumanMethylation27 Array
(Illumina, Inc., San Diego, CA). The CpG sites of the
imprinted genes were located within promoter regions, ran-
ging from 3 to 1,495 bp upstream of the transcription start
site (average distance: 426 ± 373 bp). A methylation index
(β) was obtained for each site, which is a continuous vari-
able ranging between 0 and 1 representing the ratio of the
intensity of the methylated-probe signal to the total locus
signal intensity (a β value of 0 corresponds to no methyla-
tion while a value of 1 corresponds to 100% methylation at
the specific CpG locus measured). Complete array data
have been uploaded to the Gene Expression Omnibus
(GEO) database (http://www.ncbi.nlm.nih.gov/geo/; acces-
sion number GSE26319).
Validation by quantitative DNA methylation analysis
In order to confirm methylation microarray results we car-
ried out quantitative DNA methylation analysis using
Sequenom’s EpiTYPER assay (Sequenom, Inc., San Diego,
CA). Methylation levels at WT1 were analyzed using
tumor and adjacent normal tissue DNA from five subjects
(non-pooled) for which DNA was of sufficient concentra-
tion. Analysis was conducted using pre-validated primers
from the Sequenom’s Imprinting EpiPanel designed to tar-
get imprinting control regions of known imprinted genes
(Amplicon WT1.ALT.TRANSCRIPT_05; Forward primer:
GTAGGGGTTAGGGGAGGTAAAGT; Reverse primer:
CCCAATCACAATACAACTACAATCA). Average methy-
lation levels in tumor versus normal tissue were compared
for individual CpG sites and for overallWT1methylation.
Expression confirmation in publicly available datasets
We used the Oncomine expression profiling database
version 4.4 (www.oncomine.org; accessed March 3rd,
2012) to search for expression array comparisons be-
tween prostate cancer tissue and normal tissue (either
from adjacent normal tissue or healthy controls) in five
genes with the strongest evidence of LOI in our dataset.
We searched the database for expression differences in
human prostate cancer using the gene symbol as the
keyword (e.g. “DLK1”).
Statistical analysis
The Infinium methylation data were analyzed using
Illumina's GenomeStudio software, which employs a
custom model to yield a DiffScore and p-value for each
CpG site based on a comparison of the mean methyla-
tion level in tumor tissue versus that of adjacent normal
tissue. To control for multiple comparisons, adjustments
were made in order to obtain an adjusted P value
(designed as the false discovery rate, or Q value) for each
observation using the method originally proposed by
Benjamini-Hochberg [11]. CpG sites were defined as
differentially methylated if the Q values obtained
were < 0.05. Average methylation levels derived from
SEQUENOM EpiTYPER analysis were compared be-
tween tumor and adjacent normal samples using a
two sample t-test.
Results
Global disruption of methylation at imprinted genes
Based on our analysis of a pooled sample of 12 pairs of
prostate tumor and adjacent normal tissues, our results
demonstrate an overall disruption of methylation pat-
terns of imprinted genes in tumor tissue. Among 397
CpG sites analyzed in 56 imprinted genes that were cov-
ered by the Illumina Infinium HumanMethylation27
array, the methylation index (β) in adjacent normal tis-
sues was 0.453 on average, and in prostate cancer tissue
methylation was significantly higher at 52 sites (13.1%)
and significantly lower at 17 (4.3%) sites (P < 0.05),
jointly spanning 28 unique genes (Table 1). Average per-
cent changes in the methylation index were calculated
for each of the 56 imprinted genes, in which percent
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Table 1 Methylation indices (β) for CpG sites with significant methylation changes (P < 0.05)
Gene CpG site Normal
tissue (β1)
Tumor
tissue (β2)
Change in
methylation
index (β2-β1)
Fold
change
Gene CpG site Normal
tissue (β1)
Tumor
tissue (β2)
Change in
methylation
index (β2-β1)
Fold
change
ATP10A cg10734665 0.717 0.394 −0.323 −1.820 IGF2 cg20339650 0.060 0.254 0.194 4.233
ATP10A cg11015241 0.453 0.714 0.261 1.576 IGF2AS cg13791131 0.050 0.253 0.203 5.060
CDKN1C cg05559445 0.360 0.567 0.207 1.575 INS cg25336198 0.732 0.530 −0.202 −1.381
DIRAS3 cg09118625 0.657 0.847 0.190 1.289 KCNQ1 cg06719391 0.329 0.092 −0.237 −3.576
DLK1 cg17412258 0.088 0.380 0.291 4.318 KCNQ1 cg20751395 0.847 0.690 −0.157 −1.228
DLX5 cg11500797 0.451 0.652 0.201 1.446 KCNQ1 cg17820828 0.087 0.263 0.176 3.023
DLX5 cg24115040 0.368 0.581 0.212 1.579 KCNQ1 cg12578166 0.552 0.813 0.261 1.473
DLX5 cg20080624 0.549 0.767 0.219 1.397 KCNQ1 cg01734338 0.530 0.900 0.369 1.698
DLX5 cg06537230 0.057 0.380 0.323 6.667 KCNQ1DN cg05656180 0.507 0.707 0.200 1.394
DLX5 cg06911084 0.320 0.709 0.389 2.216 KCNQ1DN cg13081704 0.557 0.759 0.202 1.363
GNAS cg01355739 0.882 0.640 −0.243 −1.378 KLF14 cg06533629 0.548 0.319 −0.229 −1.718
GNAS cg17414107 0.360 0.125 −0.235 −2.880 MEG3 cg25836301 0.558 0.745 0.187 1.335
GNAS cg06044900 0.284 0.123 −0.161 −2.309 MEG3 cg09280976 0.643 0.870 0.226 1.353
GNAS cg07284407 0.485 0.682 0.197 1.406 MEST cg09872616 0.138 0.309 0.171 2.239
GNAS cg01565918 0.457 0.720 0.263 1.575 MEST cg17347253 0.338 0.585 0.247 1.731
GNAS cg09437522 0.299 0.565 0.266 1.890 NAP1L5 cg12759554 0.714 0.407 −0.307 −1.754
H19 cg25852472 0.801 0.513 −0.288 −1.561 NNAT cg23566503 0.645 0.823 0.178 1.276
H19 cg10602543 0.790 0.560 −0.229 −1.411 NNAT cg12862537 0.712 0.903 0.191 1.268
H19 cg11492040 0.626 0.414 −0.212 −1.512 NNAT cg18433380 0.401 0.625 0.224 1.559
H19 cg23977670 0.888 0.721 −0.167 −1.232 NNAT cg10642330 0.567 0.865 0.299 1.526
HBII-437 cg08993557 0.686 0.458 −0.228 −1.498 PEG10 cg25524350 0.141 0.581 0.440 4.121
PLAGL1 cg08263357 0.429 0.678 0.249 1.580 TP73 cg25115460 0.378 0.745 0.367 1.971
PLAGL1 cg17895149 0.128 0.418 0.290 3.266 TP73 cg16607065 0.311 0.708 0.397 2.277
PLAGL1 cg25350411 0.298 0.611 0.313 2.050 WT1 cg04096767 0.463 0.670 0.207 1.447
PPP1R9A cg11164400 0.435 0.725 0.291 1.667 WT1 cg22511262 0.265 0.500 0.235 1.887
SLC22A18 cg18655584 0.677 0.860 0.182 1.270 WT1 cg15446391 0.322 0.571 0.249 1.773
SLC22A18 cg03336167 0.234 0.878 0.643 3.752 WT1 cg13301003 0.320 0.580 0.260 1.813
SLC22A3 cg25313204 0.956 0.626 −0.330 −1.527 WT1 cg01693350 0.505 0.781 0.276 1.547
SNRPN cg24993443 0.549 0.793 0.244 1.444 WT1 cg05222924 0.336 0.617 0.281 1.836
SNRPN cg11265941 0.297 0.595 0.298 2.003 WT1 cg12006284 0.315 0.724 0.410 2.298
SNRPN cg22678136 0.422 0.827 0.405 1.960 WT1 cg22533573 0.075 0.575 0.500 7.667
TCEB3C cg02432101 0.644 0.861 0.218 1.337 ZIM2 cg06244906 0.796 0.553 −0.243 −1.439
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Table 1 Methylation indices (β) for CpG sites with significant methylation changes (P < 0.05) (Continued)
TP73 cg00565688 0.580 0.230 −0.351 −2.522 ZIM2 cg02162069 0.561 0.751 0.190 1.339
TP73 cg26208930 0.601 0.866 0.265 1.441 ZIM2 cg16519742 0.635 0.867 0.232 1.365
TP73 cg03846767 0.430 0.749 0.319 1.742
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changes were averaged across the set of corresponding
CpG sites for each gene (mean number of CpG sites/
gene: 7.1 ± 6.2). Of the 56 genes, 13 demonstrated a
higher average methylation of at least 5%, and 9 demon-
strated a lower average methylation of at least 5%
(Figure 1).
Strongest evidence for methylation dysregulation at five
imprinted genes
Results from five genes were particularly notable based
on the magnitude of methylation change from adjacent
normal tissue and the consistency in the direction of
these changes across multiple CpG sites (Figure 2). CpG
site cg17412258, 212 bp upstream of the DLK1 tran-
scription start site, showed 4.32 fold higher methylation
in the tumor samples relative to the adjacent normal tis-
sue samples, with a 5% higher average methylation index
for the other CpG sites. SLC22A18 demonstrated similar
methylation changes, where 3.75 fold higher methylation
was observed at CpG site cg03336167 with a tendency
toward higher methylation at remaining sites. Three
CpG sites in the promoter region of PLAGL1 showed
statistically significant higher methylation (P < 0.05), in-
cluding 3.27 fold higher methylation at cg17895149.
Four CpG sites in the proximal TP73 promoter region
demonstrated statistically significant higher methylation
indices (1.44, 1.74, 1.97, and 2.28 fold higher methyla-
tion) (P < 0.05), while one site further upstream from the
transcription start site (917 bp) showed statistically signifi-
cantly lower methylation (P < 0.05). WT1 demonstrated
the greatest consistency in methylation aberration, with
increased methylation at 16 of 20 CpG sites. This in-
creased methylation was statistically significant (P < 0.05)
at eight CpG sites including 7.67 fold higher methylation
at cg22533573. All five of the identified genes (DLK1,
PLAGL1, SLC22A18, TP73, and WT1) have presumed
tumor suppressing functions and taken together demon-
strate a strong tendency towards higher methylation at the
CpG sites assessed.
Validation of WT1 hypermethylation by quantitative DNA
methylation analysis
We sought to confirm the hypermethylation observed
at WT1 using SEQUENOM’s EpiTYPER quantitative
methylation assay. Results were consistent with the
prior analysis by microarray, demonstrating roughly 2–
4 fold hypermethylation across all eight CpG sites ana-
lyzed in the WT1 imprinting control region (including
cg22533573, as discussed above) in comparing individual
tumor and adjacent normal tissue pairs. Averaged across
the eight analyzed CpG sites and five tumor-normal tissue
pairs with adequate DNA for this confirmation, we ob-
served a 2.04-fold increase in methylation in tumor tissue
relative to adjacent normal tissue (average normal methy-
lation level: 25.2%; average tumor methylation level:
51.4%; P = 0.0104).
Expression confirmation of differentially methylated
genes using public data
We used the Oncomine expression profiling database to
search for expression array comparisons between pros-
tate cancer tissue and prostate tissue from healthy con-
trols in DLK1, PLAGL1, SLC22A18, TP73, and WT1;
expression data for all available studies are presented in
Figure 3. Six of fourteen studies reported statistically sig-
nificant (P < 0.05) expression changes for DLK1, demon-
strating lower expression of the gene in prostate cancer
tissues relative to healthy control tissues in four studies
and higher expression in two. These studies reported
expression fold changes of −4.547 (n = 34) [12], -2.216
Figure 1 Average percent change in methylation index (β) for tumor tissue (relative to normal) across all measured CpG sites for all
imprinted genes. Numbers in parentheses indicate the number of CpG sites measured, and red bars indicate genes selected for further analysis.
Of the 56 genes, 13 demonstrated higher average methylation indices of at least 5%, and 9 demonstrated lower average methylation indices of
at least 5%.
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(n = 89) [13], -1.496 (n = 102) [14], -1.242 (n = 88) [15],
1.124 (n = 57) [16], and 1.350 (n = 21) [17], respect-
ively. Of 38 studies, 27 reported significantly lower ex-
pression of PLAGL1 in prostate cancer tissue relative
to healthy controls. These studies reported lower ex-
pression fold changes ranging from 1.143 [18] to 1.995
[17], and no study reported higher expression of the
gene in tumor tissue. Five of thirteen studies were
identified that showed significantly lower expression
for SLC22A18, with fold changes of −1.734 (n = 13)
[19], -1.411 (n = 21) [17], -1.400 (n = 26) [20], -1.341
(n = 52) [21], and −1.157 (n = 57) [16]. Four out of 22
studies showed significant WT1 expression changes, in-
cluding two studies demonstrating lower expression fold
changes of −1.315 (n = 102) [14], and −1.106 (n = 35) [22],
and two studies showing significantly higher expression
with a fold change of 1.327 (n = 21) [17] and 2.878
(n = 21) [17]. Of nine studies, one (n = 35) [22] demon-
strated a significant change in expression of TP73, with
a −1.218 fold change.
Discussion
This work represents the first comprehensive investigation
of methylation changes in prostate cancer. Our results dem-
onstrate an overall disruption of methylation at imprinted
genes in prostate cancer tissue with a greater tendency to-
ward hypermethylation than hypomethylation. Based on the
magnitude and consistency of hypermethylation across mul-
tiple CpG sites, the strongest evidence for disrupted methy-
lation patterns at imprinted genes was demonstrated at five
Figure 2 Changes in methylation in tumor tissue by CpG Site in DLK1, PLAGL1, SLC22A18, TP73, and WT1. Bars represent the percentage
change in the methylation index (β) in pooled tumor samples relative to pooled adjacent tissue samples. All measured CpG sites for the five
genes are presented.
Figure 3 Expression of five selected genes (DLK1, PLAGL1, SLC22A18, TP73, and WT1) in prostate cancer tissue relative to normal tissue
in all studies of prostate cancer identified from the publicly available Oncomine expression database. Study results are plotted according
to the -log(P-value) and expression fold-change in tumor versus normal tissue, and sample size is represented by the size of the circles (range: n = 12
to n = 160). The dotted line represents statistical significance at P = 0.05.
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tumor suppressor genes: DLK1, PLAGL1, SLC22A18, TP73,
and WT1. Of the five genes, LOI has been reported for
WT1 in Wilms’ tumor development, [23] and has not been
reported for the other four genes in the context of cancer
development. Statistically significant hypermethylation
across eight CpG sites in theWT1 imprinting control region
was confirmed using quantitative DNA methylation analysis
(P= 0.0104).
All five of the identified genes are presumed tumor
suppressors and have been reported to play roles in can-
cer development. DLK1, which encodes a transmem-
brane protein and is involved in cell differentiation, has
been linked to liver cancer development and progression
[24,25]. PLAGL1 is thought to be a transcriptional regu-
lator and has been associated with pheochromocytoma,
a tumor of the adrenal grand [26]. SLC22A18 is a trans-
porter of organic cations, and has been associated with
glioma and breast cancer progression and survival
[27,28]. WT1 plays an important role in normal develop-
ment of the urogenital system, and is named after its as-
sociation with Wilms’ tumor development [29]. It has
also been associated with breast cancer [30], colorectal
cancer [31], and thyroid cancer [32]. TP73 is an import-
ant member of the p53 family of cell cycle regulatory
proteins, which is likely disrupted in the majority of can-
cers [33,34]. Under normal imprinting control, DLK1,
PLAGL1, and WT1 are paternally expressed, while
SLC22A18 and TP73 are maternally expressed.
We hypothesized that the increased methylation ob-
served would be associated with lower expression of
these five genes, as previous research has established the
role that DNA methylation plays in regulating gene ex-
pression [35,36]. Methylation impacts gene expression
by altering chromatin structure and modifying interac-
tions between proteins and DNA [37]. Specifically,
methylated promoter CpG islands attract methyl-CpG
binding proteins and transcriptional repressors, thereby
interfering with transcription factor binding and redu-
cing transcription of the associated gene [38,39]. Ac-
cordingly, we queried the Oncomine database to
determine if expression of identified genes significantly
differed between prostate cancer and normal prostate
tissue in publicly available datasets. Evidence was pro-
vided to support a tendency towards reduced expression
in prostate tumor tissue at DLK1, PLAGL1, SLC22A18,
with less conclusive expression data for WT1 and TP73.
Taken together, our results suggest that observed
promoter hypermethylation may be involved in the
downregulation of these normally imprinted tumor
suppressor genes, which may have important func-
tional consequences for the development and progression
of prostate cancer. For example, the transmembrane pro-
tein DLK1 has been shown to negatively regulate
NOTCH1 [40], which is overexpressed in prostate cancer
and is associated with human prostate cancer cell invasion
[41]; this suggests that DLK1 downregulation may pro-
mote cell invasion via increased NOTCH1 expression.
Loss of PLAGL1 expression has been associated with pro-
gression from benign to metastatic prostate tumors via
the acquisition of androgen-independence, which enables
prostate cancers to grow in the absence of androgens [42].
Expression of SLC22A18 (also known as TSSC5) has been
observed in adult human prostate tissue and may be in-
volved in growth regulation and small molecule transport,
including the export of potentially genotoxic substances
[43]; underexpression of this protein may consequently in-
crease the risk of tumor formation. Finally, reduced ex-
pression of WT1 and TP73 proteins may have major
implications for tumorigenesis: WT1 is a transcription
factor that has been shown to regulate growth and in-
duce apoptosis when overexpressed in prostate cancer
cells [44], and p73 is a p53-family protein that is key to
apoptosis and growth arrest in human prostate cancer
cells [45].
Previous studies of loss of imprinting in prostate can-
cer have focused on TFPI2 and IGF2, with one study
reporting lower methylation in the former [8] and three
studies providing inconsistent reports of methylation
changes in the latter [7,9,46]. No significant changes in
methylation were identified in our data at TFPI2 CpG
sites, and IGF2 methylation was higher at one CpG site
and lower at the other four that were assessed. The
resulting effects on expression of these two genes were
variable across studies identified in the Oncomine ex-
pression database.
Conclusions
This study was limited by the inability to assess expres-
sion changes for our samples, as we were unable to ex-
tract sufficient RNA from our tissue samples to conduct
qPCR analyses. It should also be noted that loss of im-
printing has been previously observed in normal tissue
from cancer patients [47], which suggests that some dif-
ferential methylation events at these genes would not be
detectable in comparing tumor tissue to adjacent normal
tissue. Despite these limitations, this study represents the
first comprehensive assessment of methylation changes in
prostate cancer. Our results suggest an overall tendency
towards disruption of methylation at imprinted loci in
prostate cancer tissue, and our data provide the first sug-
gestion of disrupted imprinting patterns in cancer for four
imprinted genes (DLK1, PLAGL1, SLC22A18, and TP73).
Although our results need to be further confirmed by lar-
ger studies, these findings suggest a more widespread
dysregulation of genomic imprinting in prostate cancer
than previously reported. Future investigations such as
studying the biological significance of dysregulated im-
printing genes are also warranted.
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